Results 221 to 230 of about 2,867,204 (354)

Cost and Return on Investment of a Work-Family Intervention in the Extended Care Industry: Evidence From the Work, Family, and Health Network. [PDF]

J Occup Environ Med, 2017
Dowd WN, Bray JW, Barbosa C, Brockwood K, Kaiser DJ, Mills MJ, Hurtado DA, Wipfli B.   +7 more
europepmc   +1 more source

Frequency, Risk Factors and Antibiotic Sensitivity Pattern of Extended-Spectrum Beta-Lactamase Producing Escherichia coli and Klebsiella pneumoniae Causing Urinary Tract Infection: Experience from a Tertiary Care Hospital of Bangladesh

, 2017
Muhammad Abdur Rahim, Tabassum Samad, Palash Mitra, Shahana Zaman, Samira Humaira Habib, Samira Rahat Afroze, Wasim Md Mohosin Ul Haque, Khwaja Nazim Uddin   +7 more
openalex   +2 more sources

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Comparison of an alternative schedule of extended care contacts to a self-directed control: a randomized trial of weight loss maintenance. [PDF]

Int J Behav Nutr Phys Act, 2017
Dutton GR, Gowey MA, Tan F, Zhou D, Ard J, Perri MG, Lewis CE.   +6 more
europepmc   +1 more source

Extended data for: “But you have to start somewhere….”: Nurses’ perceptions of what is required to provide quality neonatal care in selected hospitals, Kenya.

, 2019
Mary Nyikuri, Pratap Kumar, Caroline Jones, Mike English   +3 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Shared decision-making for people living with dementia in extended care settings: protocol for a systematic review. [PDF]

BMJ Open, 2016
Daly R, Bunn F, Goodman C.
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Thigh muscle and subcutaneous tissue thickness measured using ultrasound imaging in older females living in extended care: a preliminary study. [PDF]

Aging Clin Exp Res, 2018
Welch D, Ndanyo LS, Brown S, Agyapong-Badu S, Warner M, Stokes M, Samuel D.   +6 more
europepmc   +1 more source